

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: GRUENBERG

Serial No.: 09/127,411

Filed: July 31, 1998

For: *AUTOLOGOUS IMMUNE CELL
THERAPY: CELL COMPOSITIONS,
METHODS AND APPLICATIONS TO
TREATMENT OF HUMAN DISEASE*

Art Unit: 1644

Examiner: Schwadran, R.



I hereby certify that this paper and the attached papers are being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231, on this date.

03/14/00
Date

Shelley Callagy
Shelley Callagy

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
IN ACCORDANCE WITH 37 C.F.R. § 1.97(c)**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Since this Supplemental Information Disclosure Statement is filed before the receipt of a first Office Action on the merits for the above-captioned application, no filing fee is due. If it is determined that a fee is due, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-1213.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. The Form PTO-1449 (1 page) and cited reference are provided herewith.

The documents listed on the Forms PTO-1449 and supplied herewith are in the English language. Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to


U.S.S.N. 09/127,411
GRUENBERG
INFORMATION DISCLOSURE STATEMENT

be construed as an admission by Applicant or Applicant's representative that any of the references, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

Applicant respectfully requests that the Examiner review the foregoing reference and it be made of record in the file history of the above-captioned application.

Respectfully submitted,
HELLER, EHRMAN, WHITE & McAULIFFE LLP

By:


Stephanie L. Seidman
Registration No. 33,779

Attorney Docket No. 24731-500C
Address all correspondence to:
HELLER, EHRMAN, WHITE & McAULIFFE LLP
4250 Executive Square, Suite 700,
La Jolla, California 92037
Telephone: (858) 450-8403
Facsimile: (858) 587-5360
EMAIL sseidman@hewm.com

GP-1644
#11

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: GRUENBERG


Serial No.: 09/127,411

Filed: July 31, 1998

For: *AUTOLOGOUS IMMUNE CELL
THERAPY: CELL
COMPOSITIONS, METHODS
AND APPLICATIONS TO
TREATMENT OF HUMAN
DISEASE*

Art Unit: 1644

Examiner: Schwadran, R.



I hereby certify that this paper and the attached papers are being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231, on this date.

03/14/00
Date

Shelley Callagy
Shelley Callagy

MAR 20 2000
TECH CENTER 1600/2900

TRANSMITTAL LETTER

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Transmitted herewith are a Supplemental Information Disclosure Statement, Form PTO-1449 (1 page), and cited reference for filing in connection with the above-identified application. No fee is due. If, however, it is determined that a fee is due, any fees that may be due in connection with filing this paper may be charged to Deposit Account No. 50-1213.

(X) The Commissioner is hereby authorized to charge the fee for the Information Disclosure Statement and any other fees that may be due under 37 C.F.R. §§ 1.16-1.17 in connection with this paper or with this application during its entire pendency to Deposit Account No. 50-1213. A duplicate of this sheet is enclosed.

Respectfully submitted,
HELLER, EHRMAN, WHITE & McAULIFFE LLP

By:

Stephanie L. Seidman
Stephanie L. Seidman
Registration No. 33,779

Attorney Docket No. 24731-500C
Address all correspondence to:
HELLER, EHRMAN, WHITE & McAULIFFE LLP
4250 Executive Square,
La Jolla, California 92037
Telephone: (858) 450-8400
Facsimile: (858) 587-5360
EMAIL sseidman@hewm.com